Dermatomyofibroma (plaque-like dermal fibromatosis)
Are You Confident of the Diagnosis?
Dermatomyofibroma is a rare, benign, cutaneous neoplasm. Typically it presents as an indurated, plaque-like lesion on the shoulder girdle. Often the lesion will have been present for some time with slow growth. The prototypical patient is a young to middle-aged female; however, there have have been case reports of males and children with these lesions.
Characteristic findings on physical examination
On physical examination, a dermatomyofibroma most often presents as an indurated, firm dermal plaque or nodule with or without overlying epidermal hyperpigmentation. Often these lesions are more easily palpated than seen. Dermatomyofibroma are usually seen on the upper trunk, upper arm, axilla, or neck, and are typically small with a normal size of 1 to 2cm. Larger lesions have been reported.
Expected results of diagnostic studies
Because of its rarity, dermatomyofibroma usually requires biopsy for diagnostic confirmation. Histologically, dermatomyofibroma consists of a spindle cell proliferation that is arranged in well-defined, intersecting fascicles (
Typically, specimens of dermatomyofibroma extend to the superficial subcutis and have been reported on occasion to extend into the deeper subcutis. The adnexal structures are usually spared.
Special staining of histologic specimens of dermatomyofibroma is most often useful to rule out other similarly presenting lesions, rather than rule in the diagnosis. Dermatomyofibroma stains negatively with desmin, h-caldesmon, S-100, and epithelial membrane antigen. These stains are helpful to differentiate other tumors that may be in the differential such as neurofibroma, desmoplastic spindle cell nevus, extraneural spindle cell perineurioma, and smooth muscle tumors. These lesions will stain only focally positive for actins or CD34.
There is little value in imaging studies or serologic tests in known cases of dermatomyofibroma.
The differential diagnosis of dermatomyofibroma is broad and includes the following entities: connective tissue nevus, cutaneous myofibroma, dermatofiboma, dermatofibrosarcoma protuberans, desmoplastic spindle cell nevus, extraneural spindle cell perineurioma, fibrous hamartoma of infancy, hypertrophic scar, neurofibroma, pilar leiomyoma, smooth muscle tumors. Some of these entities will be distinguished by clinical history, presence at birth, recent trauma, etc; however, histologic diagnosis is paramount.
Who is at Risk for Developing this Disease?
Dermatomyofibroma typically occur in young to middle-aged females, with rare reports of lesions in children and males. Dermatomyofibroma are rare lesions in and of themselves. It has been theorized that dermatomyofibroma in male children may regress spontaneously after childhood more often than in females.
What is the Cause of the Disease?
The etiology of dermatomyofibroma is unknown, but it is described as a benign proliferation of fibroblasts and myofibroblasts.
Systemic Implications and Complications
Currently, there are no known systemic implications of dermatomyofibroma. These lesions are rare enough, however, that such a correlation would be very difficult to recognize.
Treatment options for dermatomyofibroma are summarized in the
|Medical Treatment||Surgical Procedures||Physical Modalities|
Optimal Therapeutic Approach for this Disease
- Reassurance and watchful waiting is the optimal treatment in the majority of cases.
- Lesions have been reported to self-resolve, more often in males after puberty.
- If treatment is desired, surgical excision is the only method of complete removal.
Explanation of the benign nature of these lesions is usually all that is required for patient care. Biopsy will usually be required for definitive diagnosis as dermatomyofibroma clinically presents with a broad differential diagnosis.
Unusual Clinical Scenarios to Consider in Patient Management
Given the vague clinical presentation of these lesions, biopsy is usually warranted for more definitive diagnosis. Once diagnosis is established, there are no special scenarios of which to be aware. These are rare neoplasms, but benign.
What is the Evidence?
Gilaberte, Y, Coscojuela, C, Doste, D, Vera, J, Requena, L. "Dermatomyofibroma in a male child". J Eur Acad Dermatol Venereol. vol. 10. 2005. pp. 257-59.(Report of dermatomyofbroma in a male child.)
Hugel, H. "Plaque-like dermal fibromatosis/dermatomyofibroma". J Cutan Pathol. vol. 20. 1993. pp. 94.(A review of dermatomyofibroma.)
Kamino, H, Reddy, VB, Gero, M, Greco, MA. "Dermatomyofibroma. A benign cutaneous plaque-like proliferation of fibroblasts and myofibroblasts in young adults". J Cutan Pathol. vol. 19. 1992. pp. 85-93.(A review of dermatomyofibroma in young adults.)
Mentzel, T, Kutzner, H. "Dermatomyofibroma: clinicopathologic and immunohistochemical analysis of 56 cases and reappraisal of a rare and distinct cutaneous neoplasm". Am J Dermatopathol. vol. 31. 2009. pp. 44-9.(A case series of dermatomyofibromas.)
Mortimore, RJ, Whitehead, KJ. "Dermatomyofibroma: a report of two cases, one occurring in a child". Australas J Dermatol. vol. 42. 2001. pp. 22-5.(Case reports of dermatomyofibroma in childhood.)
Rose, C, Brocker, E. "Dermatomyofibroma: Case report and review". Pediatr Dermatol. vol. 16. 1999. pp. 456-9.(Case report and review of dermatomyofibroma.)
Copyright © 2017, 2012 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- St John's Wort and Cancer
- Radiation Therapy Increases 5-year Rate of Cardiac Events in Small-cell Lung Cancer
- Long-term Survival From Ipilimumab/Nivolumab Combination in Metastatic Melanoma
- Questions Remain for First-line Treatment Selection and Sequencing in Advanced Melanoma
- Pazopanib: Where Does It Stand as Adjuvant Therapy in Localized RCC?
- Lung Cancer Treatment in North America: Recent Advances and Future Promises
- Atezolizumab Maintains Clinical Benefit After 2 Years in Advanced NSCLC
- Luminespib May Be Effective in NSCLC With EGFR Exon 20 Insertion Mutation
- Pembrolizumab After Locally Ablative Therapy May Be Beneficial in Metastatic NSCLC
- Liquid Biopsies Detect Unknown Driver Mutations in Advanced NSCLC